BAs such as anti-IgE, anti-IL5, and anti-IL-4/IL-13 monoclonal antibodies (mAb) were found to be effective in the CRSwNP treatment of patients with severe asthma, with the most significant reduction being observed in the anti-IL-4R-mAb-receiving group [28]. The gene discussed is IL4R; the disease is asthma.